Kenichi Ishizawa
4PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jul 24, 2023
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Wataru Munakata, Koji Izutsu, Yuko Mishima
|Oct 13, 2022
Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes.Kentaro Watanabe, Noe Takakubo, Taro Saigusa
|Sep 08, 2022
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.Tadao Ishida, Shigeki Ito, Junji Tanaka
|Jul 07, 2022
A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.Kenichi Ishizawa, Masahiro Yokoyama, Harumi Kato
Pageof 1
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=75)